Despite much recent progress, prostate cancer continues to represent a major cause of
cancer-related mortality and morbidity in men. Since early studies on the role of the …

Background Castration-resistant prostate cancer (CRPC) occurs when prostate cancer
(CaP) progresses under therapy-induced castrate conditions. Several mechanisms have …

Prostate cancers that are progressing on medical and surgical therapies designed to ablate
the action of androgens continue to express androgen receptor (AR) and to depend on …

Although systemic androgen deprivation prolongs life in advanced prostate cancer,
remissions are temporary because patients almost uniformly progress to a state of a …

The classical action of androgen receptor (AR) is to regulate gene transcriptional processes
via AR nuclear translocation, response element binding and recruitment of, or crosstalk with …

A recently developed adenine base editor (ABE) efficiently converts A to G and is potentially
useful for clinical applications. However, its precision and efficiency in vivo remains to be …

Androgens play pivotal roles in the regulation of male development and physiological
processes, particularly in the male reproductive system. Most biological effects of androgens …

The cross-regulation of Wnt/β-catenin/Tcf ligands, kinases, and transcription factors with
members of the nuclear receptor (NR) family has emerged as a clinically and …

Understanding normal and cancer stem cells may provide insight into the origin of and new
therapeutics for prostate cancer. Normal and cancer stem cells in prostate have recently …

Androgen deprivation therapy is the major treatment for advanced prostate cancer (PCa).
However, it is a temporary remission, and the patients almost inevitably develop hormone …